Literature DB >> 20049444

Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy.

Wan-Hee Yoo1.   

Abstract

A case of multiple organ tuberculosis (TBc) involving lung, pleura, and peritoneum in a 39-year-old man with long-standing ankylosing spondylitis (AS) treated with adalimumab was presented. The relationship between antitumor necrosis factor-α (anti-TNF-α) therapy and TBc was also reviewed. This case illustrates that TBc can develop in multiple organs during adalimumab therapy, and thus, the awareness of serious complications of multiple organs and atypical extrapulmonary pattern of TBc during anti-TNF-α therapy needs to be increased.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049444     DOI: 10.1007/s00296-009-1357-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study.

Authors:  Giovanni Ferrara; Monica Losi; Roberto D'Amico; Pietro Roversi; Roberto Piro; Marisa Meacci; Barbara Meccugni; Ilaria Marchetti Dori; Alessandro Andreani; Barbara Maria Bergamini; Cristina Mussini; Fabio Rumpianesi; Leonardo M Fabbri; Luca Richeldi
Journal:  Lancet       Date:  2006-04-22       Impact factor: 79.321

Review 2.  Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.

Authors:  Jeffry Bieber; Arthur Kavanaugh
Journal:  Rheum Dis Clin North Am       Date:  2004-05       Impact factor: 2.670

3.  Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays.

Authors:  A L Endean; S M Barry; S A Young-Min
Journal:  Rheumatology (Oxford)       Date:  2008-12-24       Impact factor: 7.580

Review 4.  Adalimumab: a review of side effects.

Authors:  Noah Scheinfeld
Journal:  Expert Opin Drug Saf       Date:  2005-07       Impact factor: 4.250

Review 5.  Infections associated with tumor necrosis factor-alpha antagonists.

Authors:  David J Rychly; Joseph T DiPiro
Journal:  Pharmacotherapy       Date:  2005-09       Impact factor: 4.705

Review 6.  Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.

Authors:  Anja Strangfeld; Joachim Listing
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-12       Impact factor: 4.098

7.  Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab.

Authors:  Valdeŕilio Feijó Azevedo; C Parchen; S A Coelho; D C Lacerda; C G Hirth
Journal:  Rheumatol Int       Date:  2009-01-14       Impact factor: 2.631

8.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Authors:  Daniel E Furst; Michael H Schiff; Roy M Fleischmann; Vibeke Strand; Charles A Birbara; Daniele Compagnone; Steven A Fischkoff; Elliot K Chartash
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

9.  Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

Authors:  Aparna K Mohan; Timothy R Coté; Joel A Block; Augustine M Manadan; Jeffrey N Siegel; M Miles Braun
Journal:  Clin Infect Dis       Date:  2004-07-16       Impact factor: 9.079

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  5 in total

1.  Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

Authors:  Steffen Hess; Toni Hospach; Robert Nossal; Günther Dannecker; Klaus Magdorf; Frank Uhlemann
Journal:  Eur J Pediatr       Date:  2011-05-31       Impact factor: 3.183

2.  Epidemiology of Mycobacterium bovis disease in humans, The Netherlands, 1993-2007.

Authors:  Christof J Majoor; Cecile Magis-Escurra; Jakko van Ingen; Martin J Boeree; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

3.  Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report.

Authors:  Jae Hong Oh; Seung Pil Ham; Hai-Jin Park
Journal:  Ann Dermatol       Date:  2020-12-30       Impact factor: 1.444

4.  Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis.

Authors:  Olívia Meira Dias; Daniel Antunes Silva Pereira; Bruno Guedes Baldi; André Nathan Costa; Rodrigo Abensur Athanazio; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2014 Jan-Feb       Impact factor: 2.624

5.  Posterior surgical treatment of ankylosing spondylitis with spinal tuberculosis: A case series and long-term follow-up.

Authors:  Xin Hua Yin; Shi Chang Liu; Ming Yang; Bao Rong He; Zhong Kai Liu; Ding Jun Hao
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.